Biostage, Inc. Common Stock
BSTG
BSTG was delisted on the 5th of October, 2017.
24 hedge funds and large institutions have $1.14M invested in Biostage, Inc. Common Stock in 2017 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 7 reducing their positions, and 3 closing their positions.
19% more capital invested
Capital invested by funds: $961K → $1.14M (+$182K)
0% more funds holding
Funds holding: 24 → 24 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
29% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$72K |
| 2 |
Renaissance Technologies
New York
|
+$26.6K |
| 3 |
GWI
Grace & White Inc
Ny,
New York
|
+$9.53K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$9.5K |
| 5 |
Bank of New York Mellon
New York
|
+$5.91K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$17K |
| 2 |
WIC
Woodmont Investment Counsel
Nashville,
Tennessee
|
-$11.8K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$10.1K |
| 4 |
Wells Fargo
San Francisco,
California
|
-$9K |
| 5 |
VKH
Virtu KCG Holdings
New York
|
-$4.83K |
BSTG Hedge Fund Activity: Q2 2017 in Review
24 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Biostage, Inc. Common Stock (BSTG) for Q2 2017, worth a combined $1.14M — up 19% from $961K a quarter earlier.
Fund positioning in BSTG was balanced in Q2 2017: 3 funds opened new positions, 3 closed out, 5 added to existing stakes and 7 trimmed.
The largest buyer was Panagora Asset Management, adding an estimated $72K. The largest seller was Citadel Advisors, exiting entirely with an estimated $17K sold.
- 24 institutional investors held Biostage, Inc. Common Stock (BSTG) as of Q2 2017, unchanged from Q1 2017.
- Funds reported $1.14M of Biostage, Inc. Common Stock stock for Q2 2017, up 19% quarter-over-quarter.
- 3 funds opened new Biostage, Inc. Common Stock positions in Q2 2017 and 3 closed out, a net change of 0 holders.
- The largest Biostage, Inc. Common Stock buyer in Q2 2017 was Panagora Asset Management, an estimated $72K added.
- The largest Biostage, Inc. Common Stock seller in Q2 2017 was Citadel Advisors, an estimated $17K sold.
Based on aggregated 13F filings for Q2 2017.